 Home > Medical News > Medicines Company News > TD Biologics announces the latest clinical trial progress of the CFI-402257 and CFI-400945 programs at the 2022 San Antonio Breast Cancer Conference

TD Biologics announces the latest clinical trial progress of the CFI-402257 and CFI-400945 programs at the 2022 San Antonio Breast Cancer Conference

 Last Update: 2023-01-05
 Source: Internet
 Author: User

Tags

what cancer antigen

john 7 14

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

TD Biologics, a clinical-stage biotechnology company developing new drugs for highly aggressive cancer, announced on November 21 that it has published four abstracts focused on CFI-402257 and CFI-400945, the Company's potent and selective TTK and PLK4 inhibitors, which have been accepted for the work of Henry B.
B.
Presented
at the 2022 San Antonio Breast Cancer Symposium (SABCS) held at the Gonzalez Convention Center.

Dr.
Michael Tusche, Co-CEO of TD Biologics, said, "We are honored that several of our abstracts highlighting TTK and PLK4 inhibitor programs have been selected for presentation
at the conference.
We look forward to more data from these studies that will allow us to gain a better understanding
of the utility of our pipeline products in a variety of breast cancer settings.
" "

Information on the four abstracts:

SUMMARY: Recent advances in the Phase 1 clinical trial of CFI-402257 (oral TTK inhibitor) in patients with advanced solid tumors in the HER2-negative breast cancer expansion cohort

Poster ID： P6-10-13

Session: Therapeutics: Therapeutic Strategies - New Targets and Targeted Drugs

Date: Friday, December 9, 2022

Time: 7:00 a.
m.
Central Time

SUMMARY: CCTG IND.
236: Phase 1b trial of CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC).

Poster ID： P3-07-10

Session: Therapeutic: Therapeutic Strategies - New Drugs and Therapeutic Strategies

Date: Wednesday, December 7, 2022

Time: 5:00 p.
m.
Central Time

SUMMARY: CCTG IND.
237: CFI-400945 Phase 2 clinical study in patients with advanced/metastatic HER2-negative breast cancer

Poster ID： P3-07-14

Date: Wednesday, December 7, 2022

Time: 5:00 p.
m.
Central Time

ABSTRACT: CCTG IND.
239: A Phase 2 clinical study of CFI-400945 and durvalumab in patients with advanced triple-negative breast cancer (aTNBC).

Poster ID： P3-07-18

Date: Wednesday, December 7, 2022

Time: 5:00 p.
m.
Central Time

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.